Sialic acid moiety on host respiratory epithelial cell (SA moiety)

Sialic acid moieties on host respiratory epithelial cells are terminally located monosaccharide derivatives found on cell-surface glycoconjugates, such as glycoproteins and glycolipids[1][7]. They contribute to the negative charge of the cell surface, forming an electrostatic shield that protects tissues against proteolytic attack and modulates cell-cell interactions[1]. These moieties play critical roles in cell recognition, immune function, and epithelial barrier integrity. In the respiratory tract, the diversity of sialic acid linkages (primarily α2,6- and α2,3-linked sialic acids) determines tropism of respiratory viruses such as influenza and coronaviruses, with human strains preferentially binding α2,6-linked forms[4][7]. Modifications to sialic acid structures, such as O-acetylation, further influence susceptibility to infection and pathogen-host specificity[6]. Pathological changes in sialic acid presentation and sialylation, regulated by enzymes such as sialyltransferases, are implicated in diseases like asthma, cancer, and viral respiratory infections[2][4][7]. Therapeutic targeting can occur via modulation of sialylation or by inhibiting pathogen–sialic acid interactions, but must contend with the crucial physiological roles of these glycans in tissue health[1][2].

Other names

Sialic acidSialylated glycanSialoglycanCell-surface sialylated oligosaccharideSialic acid receptorSialic acid-linked glycoproteinSAα2,6Gal (alpha 2,6-linked sialic acid)SAα2,3Gal (alpha 2,3-linked sialic acid)

- Blockade of viral binding: Some molecules compete with or mask sialic acid binding sites, preventing viral attachment[3][4][5][7]. - Enzyme inhibition: Inhibit neuraminidase/sialidase activity, retaining sialic acid on host cells and limiting viral release/spread (influenza-focused)[5]. - Alteration of glycosylation/sialylation: Modulate host cell sialylation patterns to reduce pathogen binding or change cellular responses[2].